医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

AmpliPhi Biosciences Announces Presentation of Preclinical Data Demonstrating that AB-PA01 Reduces Biofilm in Pseudomonas aeruginosa In Vivo Model

2018年03月09日 PM08:50
このエントリーをはてなブックマークに追加


 

SAN DIEGO

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the presentation of in vivo preclinical data showing AB-PA01 reduces biofilm in a Pseudomonas aeruginosa preclinical model. The data were presented at the Australian Society of Otolaryngology Head and Neck Surgery 68th Annual Scientific Meeting, being held March 9-11, 2018 in Perth, Western Australia.

The presentation, titled “Efficacy and safety of a Pseudomonas aeruginosa bacteriophage cocktail in a sheep model of rhinosinusitis” will be delivered by Dr. Stephanie Fong on Saturday, March 10, 2018, at 1:40 p.m. local time in Crown Ballroom 1, Concurrent Session 10 – Rhinology, at the Crown Perth Convention Centre.

“The data presented demonstrate the potential of bacteriophage therapeutics by clearly showing AB-PA01’s effectiveness in reducing biofilm in vivo, a major obstacle in the treatment of Pseudomonas aeruginosa and its associated symptoms,” said Peter-John Wormald, M.D., Professor of Otolaryngology Head & Neck Surgery at the University of Adelaide and Principal Investigator for AmpliPhi’s already completed Phase 1 study, “I believe bacteriophage therapeutics hold much promise and this study adds to the growing body of supportive evidence.”

A sheep rhinosinusitis model was adapted to simulate Pseudomonas aeruginosa infection in sheep frontal sinuses. To assess efficacy, after a 7-day biofilm formation period, sheep received twice-daily flushes of AB-PA01 or saline for one week. Biofilm quantitation on the frontal sinus mucosa was performed using BacLight LIVE/DEAD stain. The study showed a statistically significant reduction in biofilm biomass with AB-PA01 compared to control (p<0.05). No safety concerns were noted.

About AmpliPhi Biosciences

AmpliPhi Biosciences Corporation is a clinical-stage biotechnology company focused on treating antibiotic-resistant infections using its proprietary bacteriophage-based technology. AmpliPhi’s lead product candidates target multidrug-resistant Staphylococcus aureus and Pseudomonas aeruginosa, which are included on the WHO’s 2017 Priority Pathogens List. Phage therapeutics are uniquely positioned to address the threat of antibiotic-resistance as they can be precisely targeted to kill select bacteria, have a differentiated mechanism of action, can penetrate and disrupt biofilms (a common bacterial defense mechanism against antibiotics), are potentially synergistic with antibiotics and have been shown to restore antibiotic sensitivity to drug-resistant bacteria. For more information visit www.ampliphibio.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180309005159/en/

CONTACT

At the Company:
AmpliPhi Biosciences
Matthew Dansey,
(858) 800-4869
md@ampliphibio.com
or
Investor
Relations:

Westwicke Partners
Robert H. Uhl, (858) 356-5932
robert.uhl@westwicke.com
or
Media:
Russo
Partners, LLC
David Schull or Maggie Beller
(212) 845-4271
David.Schull@RussoPartnersLLC.com
Maggie.Beller@RussoPartnersLLC.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc
  • 瑞思迈首款最小接触型全脸CPAP面罩AirFit F30现已在美国和加拿大发售
  • AVITA Medical Announces First U.S. Sales of RECELL® System and Commencement of Commercial Shipping
  • PotNetwork Holdings, Inc.在注册成为SEC报告公司之后发布PCAOB经审计和审核的完整财务报表
  • PotNetwork Holdings, Inc.提交Form 10以成为美国证券交易委员会报告公司